Organogenesis Holdings Inc. Reports Fourth Quarter 2023 and Fiscal Year 2023 Financial Results; Introduces Fiscal Year 2024 Guidance

February 29, 2024

https://www.globenewswire.com/news-release/2024/02/29/2838395/0/en/Organogenesis-Holdings-Inc-Reports-Fourth-Quarter-2023-and-Fiscal-Year-2023-Financial-Results-Introduces-Fiscal-Year-2024-Guidance.html

CANTON, Mass., Feb. 29, 2024 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq:ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the fourth quarter and the year ended December 31, 2023.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.